• news.cision.com/
  • Integrum AB/
  • Integrum signs an agreement with the Center of Rehabilitation, University Medical Center, Groningen to become the first Neuromotus™ Teaching Center in the world.

Integrum signs an agreement with the Center of Rehabilitation, University Medical Center, Groningen to become the first Neuromotus™ Teaching Center in the world.

Report this content

The University Medical Center Groningen and Integrum sign an agreement for the UMCG Center of Rehabilitation to become the first Neuromotus™ Teaching Hospital, and train fellow clinicians in its usage in combatting phantom limb pain.

Located approximately 200 kilometers from the nation’s capital, The University Medical Center Groningen (UMCG) is one of the largest hospitals in the Netherlands, and is the largest employer in the Northern Netherlands. UMCG focuses on care, education, training, and research; and not only provides patient-centred care, but also aims to conduct revolutionary scientific and educational research on treating the healthy aged population. This in order to to build the future of healthcare, and a healthy and active population.

Committed to these values, the UMCG is one of the pioneering medical centers which has introduced Neuromotusto treat phantom limb pain (PLP). Now, as a Neuromotus™ Teaching Center, the Center of Rehabilitation at UMCG will be equipped to train other clinicians and teams who are intending to introduce this novel, non-invasive, Augmented Reality based technology in the treatment of their patients. This provides Integrum with a broader access to rehabilitation centers who treat PLP patients, and provides further clinics, and consequently patients, access to the novel and effective therapy. 

The efficient and highly skilled team, led by Professor, Dr. Corry van der Sluis, is driving the Neuromotusproject at the UMCG. The multidisciplinary team is composed of a group of researchers, doctors, and therapists. Since the first patient was recruited in 2016, UMCG has utilized Neuromotus to treat several amputees suffering from debilitating PLP.

One of the biggest challenges in the healthcare field is the translation of results generated through scientific research into a clinical environment, and demonstrating tangible clinical benefits. Promising research which fails to achieve this goal is, unfortunately, a common occurrence. However, with the support of the University of Groningen, a strong and multidisciplinary team, and a seamless collaboration with Integrum, the Rehabilitation Center at UMCG has been able to translate Neuromotus into a clinical setting and derive its intended patient benefits. 

“Introducing innovation to the standard of care is always a challenge, but with strong and productive collaborations such as the one we have with the UMCG, the efforts towards achieving our mission of helping as many people as possible with amputation, is made easier.”-Maria Lopez, CEO, Integrum AB.

About Neuromotus™

Phantom Limb Pain is debilitating condition which affects approximately 50-80% of people with amputation, and current treatment modalities such as “mirror therapy” and the use of heavy opiates have proven ineffective with many patients. Neuromotus™ is a novel, non-invasive device which is based on the principles of Phantom Motor Execution and utilizes Augmented Reality technology to “train away the pain”. Clinical evidence clearly demonstrates a significant reduction of PLP for even chronic patients. 

For further information, please contact:
Maria Lopez, CEO
Cell. +46 (0) 708-46 10 69
Email: maria.lopez@integrum.se

Certified Adviser:
Erik Penser Bank AB
Tel. +46 (0) 8 463 8000
Email: certifiedadviser@penser.se

Integrum AB is a publicly-traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 14 countries has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the US Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation. In December 2020, Integrum successfully completed the most stringent medical device regulatory procedure in the world, and based on the solid scientific data submitted, was granted a PMA by the FDA for the OPRATM Implant System, which is the only technology approved for above knee, bone-anchored prosthetics in the U.S. More information on the company and its innovative solutions for amputees can be found at www.integrum.se


Documents & Links